Patient‐reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma

20260 citationsJournal Article

Authors

The addition of trastuzumab to CRT for localized HER2+ EAC did not improve PROs.

Zero hunger

Published in: Cancer

Volume 132, Issue 6, pp. e70345-e70345

Field-Weighted Citation Impact: 0.00